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Abstract 
Background: The process of translating preclinical findings into a 
clinical setting takes decades. Previous studies have suggested that 
only 5-10% of the most promising preclinical studies are successfully 
translated into viable clinical applications. The underlying 
determinants of this low success rate (e.g. poor experimental design, 
suboptimal animal models, poor reporting) have not been examined 
in an empirical manner. Our study aims to determine the 
contemporary success rate of preclinical-to-clinical translation, and 
subsequently determine if an association between preclinical study 
design and translational success/failure exists. 
Methods: Established systematic review methodology will be used 
with regards to the literature search, article screening and study 
selection process. Preclinical, basic science studies published in high 
impact basic science journals between 1995 and 2015 will be included. 
Included studies will focus on publicly available interventions with 
potential clinical promise. The primary outcome will be successful 
clinical translation of promising therapies - defined as the conduct of 
at least one Phase II trial (or greater) with a positive finding. A case-
control study will then be performed to evaluate the association 
between elements of preclinical study design and reporting and the 
likelihood of successful translation. 
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Discussion: This study will provide a comprehensive analysis of the 
therapeutic translation from the laboratory bench to the bedside. 
Importantly, any association between factors of study design and the 
success of translation will be identified. These findings may inform 
future research teams attempting preclinical-to-clinical translation. 
Results will be disseminated to identified knowledge users that 
fund/support preclinical research.
Keywords 
Translational failures, promising therapies, bench-to-bedside 
research, systematic review, case-control study
Any reports and responses or comments on the 
article can be found at the end of the article.
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Introduction
Advances in discovery research form the backbone for the 
development of novel therapeutics. Such translation relies on a 
“process of turning observations in the laboratory, clinic, and 
community into interventions that improve the health of 
individuals and the public�1. The process is often visualized as 
a linear model (Figure 1). In reality, however, it comprises a 
spectrum that masks the complex, iterative and interdiscipli-
nary research and development steps that engage multiple 
stakeholders2,3. As a result, the successful translation of 
promising preclinical discovery research into human studies 
(T1) is rare4, and the resource-intensive efforts to evaluate 
Figure 1. The translational research spectrum.
discoveries in sufficient detail to allow them to be available for 
patients (T2) takes decades rather than years5.
While discovery research has inherent value, funding agencies 
around the world are increasingly focused on improving the 
success of “bench to bedside� translation (T0-T2), thereby 
enhancing the potential impact of biomedical research budgets. 
Certainly, there is great potential for improvement; it is 
estimated that the US alone invests 28 billion dollars per year 
on research that cannot be reproduced6. Importantly, a clinically 
translated therapy – one which has obtained regulatory approval 
– does not mean patients will have access to it. An additional 
hurdle in the translation into practice (T3) and community (T4) 
access is whether or not insurance companies and healthcare 
systems will pay for the therapy. The willingness to pay is 
largely dependent on a cost-comparative analysis of the 
potential therapy as well as the needs and resources of the 
jurisdiction. As this is a critical aspect in the translation spectrum 
and widespread use of a therapy, it has been thoroughly 
investigated7.
Investigation of translation in the earlier phases of the trans-
lational spectrum – from basic research (T0) to clinical trials in 
humans (T2) – has uncovered striking deficits when mov-
ing from one phase to another8. These inefficiencies ultimately 
contribute to a 5–10% rate of successful translation of 
preclinical “bench� research to approved therapies. This means 
that approximately 90% of promising discoveries may not 
directly contribute to improved human health5,9,10. Moreover, 
translation failures expose clinical research participants to 
potential harms of investigational products that fail on safety 
or efficacy grounds11,12. The extent of translational failures 
diverts scarce funding away from developing interventions that 
are more likely to benefit patients. Given the recent focus on 
research waste13–16, it is abundantly clear that bench-to-bedside 
translation needs solutions to become more efficient.
Three highly cited studies investigating this issue in publicly-
available data have been previously published. Contopoulos-
Ioannidis et al.17 traced the translation of published, highly 
promising in vivo basic science findings into clinical applica-
tions from 1979 to 1983 in six basic science journals. They iden-
tified 101 promising therapies and in 2003 (i.e. ~20 years since 
studies published), 27 entered clinical trials and only 5 were 
clinically licensed (i.e. only 5% translated into an approved 
therapeutic). Hackam and Redelmeier10 searched for studies 
published in seven leading journals between 1980 and 2000 
that were cited >500 times and investigated highly promising 
preclinical agents. Their inclusion criteria resulted in 76 studies 
of interventions, of which 42 (55%) entered clinical trials and 
only 8 (10%) were approved for clinical use. These authors 
attempted multivariable analyses to identify predictors of 
      Amendments from Version 1
We thank both reviewers for their assessment. In response, we 
have made the following changes:
1.    We updated citation 4 and 6 for more recently published 
references.
2.    We removed the three sentences about return on 
investments of medical research (reference 7), as it may not be 
the best argument to make in the introduction.
3.    We have modified the beginning of a sentence in the 
manuscript to further explain the aim of this project: Therefore, 
the aim of this project is to use established knowledge synthesis 
methods to identify the prevalence of translation from preclinical 
research (bench) to the first clinical evaluations of efficacy 
(bedside)…
4.    We added blood products and implants/devices as examples 
of ‘promising therapies’ in the inclusion criteria.
5.    We added the following sentence in the analysis plan of 
Objective 1: Additionally, we will calculate the proportion of 
successful Phase II trials that received regulatory approval. 
6.    We changed sentence about deviations to: Any deviation 
from this protocol will be documented in the manuscript that 
reports the results of this study, upon its completion.
7.    We added the following to the limitations section: 
Furthermore, our sample is limited to three journals, which may 
reduce the scope of our work. As automation of meta-research 
projects gains traction (and tools are validated) broader searches 
will certainly be possible in the future. However, given that this 
process currently relies on personnel we are limited to the 
current strategy.  
8.    We have modified the following in our limitations section: 
a)    Though ultimate clinical translation is the approval and 
adoption of a therapy, we will focus on a specific stage in the 
translational spectrum 4…
b)    … and regulatory approval may not guarantee widespread 
adoption. With this limitation in mind, …or barriers that affect 
both regulatory approval and adoption into practice.
Any further responses from the reviewers can be found at 
the end of the article
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translation; however, the small sample size “limited power to 
discern individual predictors of translation.� In the most recent 
investigation of this issue, Morris et al.18 (2011) performed a 
pseudo-systematic search to identify studies that had quanti-
fied time lags in the development of health interventions. They 
found time lags of ~20 years for interventions to translate, 
though this depended on how each study defined if transla-
tion occurred. Importantly, they concluded that the “knowledge 
of time lags is of limited use to those responsible for R&D…
who face difficulties in knowing what they should or can do to 
reduce time lags.� In other words, identifying fac-
tors associated with successful translation of preclinical 
research into clinical trials may be a more practical metric 
than time lags for decision makers.
In considering this previous research, it is still currently 
unknown if/how rates of translation from preclinical research 
to the therapy’s evaluation in clinical trials are associated with 
study rigor (i.e. internal validity, risk of bias), and external 
validity (i.e. reproducibility over a range of conditions), 
among other factors affecting the quality of the preclinical evi-
dence such as construct validity (i.e. the experimental model 
appropriately represents the clinical condition and setting). 
Therefore, the aim  of this project is to use established knowl-
edge synthesis methods to identify the prevalence of trans-
lation from preclinical research (bench) to the first clinical 
evaluations of efficacy (bedside), map contemporary trends in 
translation, and identify key modifiable factors associated with 
successful and unsuccessful bench-to-bedside translation.
Objectives
Objective #1 
We will perform a cross-sectional study to estimate the rate of 
publicly available bench-to-bedside translation. Specifically, 
we will identify published preclinical1 research of promising 
therapies and track how far along the translational 
spectrum they have progressed.
Regulatory approval of the therapy will be considered 
successful translation. If approval has not yet been obtained, 
we will consider a therapy that translated from the preclinical 
phase (T0) to a Phase II clinical trial (T2) or further, a successful 
bench-to-bedside translation.
Objective #2
We will next perform a case-control study to identify fac-
tors associated with therapies that have been success-
fully translated from the preclinical study in which it was 
identified, to a positive clinical trial evaluating treatment 
efficacy. Specifically, we will consider a therapy to be ‘success-
fully’ translated if it 1) has obtained regulatory approval, or 
2) has a significant, positive finding in a clinical trial evaluating 
efficacy (presumably a Phase II trial) at the latest stage trial the 
therapy has advanced to (i.e. the therapy will not be considered 
successful if it demonstrated efficacy in an earlier trial and 
subsequently showed null or negative findings in a later efficacy 
trial).
Methods
Protocol
Any deviation(s) from this protocol will be documented in 
the manuscript that reports the results of this study, upon its 
completion
Objective #1
The first objective of this study is to estimate the rate of 
translation from preclinical research in animal models to 
success in phase II clinical studies of therapeutic efficacy. This 
will be achieved through a cross-sectional study of preclinical 
investigations. In order to identify and select relevant studies 
for inclusion, we will employ methods typically used in 
systematic reviews19. The objective focuses on two questions. 
What is the current rate of preclinical to clinical transla-
tion of promising basic science findings? What are the basic 
characteristics and design features of the promising therapies 
identified?
Eligibility criteria. We will identify preclinical studies pub-
lished in Science, Nature, and Nature Medicine. These journals 
were selected because they are considered leaders across all 
domains of preclinical research and are anticipated to publish 
work that may impact human health. Our selection also reflects 
the philosophy adopted by the largest previous evaluation of 
bench-to-bedside research5.
Eligible articles will be those published between 1995 and 
2015. This timeframe allows a significant time-lag (although 
not necessarily the full ~20-year time lag described previ-
ously). This timeframe will also allow for an evaluation of (in an 
exploratory manner) whether bench-to-bedside translation 
has improved in terms of both time-lags and the proportion of 
therapies advancing to later phases of clinical trials or gaining 
regulatory approval. Importantly, we anticipate that the journal 
selection and year range will also provide an adequate sample size 
to perform the case-control study outlined in Objective #2.
Inclusion criteria
i. Population:
Articles that describe a preclinical, interventional study: any 
article that includes in vivo non-human animal experiments 
that has not been tested for the same purpose in humans prior to 
the study.
ii. Intervention and outcome:
A ‘promising therapy’, defined by the following:
a.     Any therapy introduced to the animal model (i.e. phar-
macologic and non-pharmacologic therapies, vaccines, 
antibodies, blood products, implants/devices, etc.), 
which was still at the developmental stage and did 
not have a prior application in humans for the specific 
indication.
1 The term ‘preclinical’ has variable definitions, depending on the context. 
For the purposes of this study, our group has chosen to focus on preclinical 
interventional in vivo animal experiments, relevant to the betterment of human 
health and/or treatments for human disease.
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b.     Novel uses of existing therapies (e.g. treatment of a 
different disease) will also be included.
c.     The intervention must induce an outcome that 
positively benefits an indicator of health of the animal 
(e.g. an immunotherapy that shrinks solid tumor size in 
the animal model) and/or investigators state that the 
therapy should be translated clinically based on their 
findings.
iii. Comparison:
Any comparison to the intervention will be acceptable
Exclusion criteria
 i.      Editorials, commentaries, reviews, news articles, articles 
that focus on a mechanism of action, pathophysiology, 
or diagnosis, and articles on agricultural or veterinary 
applications that would not be feasibly applied to 
humans.
ii.      Investigators explicitly state that translation should not 
be attempted based on the study.
iii.      Ex vivo, in vitro, and human clinical trials.
Information sources and search strategy. All included 
journals are indexed in MEDLINE, therefore this database will 
be searched from January 1st, 1995, to December 31st, 2015. A 
validated animal filter will limit results to animal studies20. The 
search strategy will be developed and finalized with the help 
of an information specialist who has expertise in the design of 
systematic searches (L. Sikora). The search strategy can be 
found in Extended data21.
Study selection process. The literature search results will be 
uploaded to Distiller Systematic Review Software (DistillerSR®, 
Evidence Partners, Ottawa, Canada). DistillerSR is an audit-
ready, cloud-based software program that allows for transparent 
and reproducible work required for an accurate review. Two 
reviewers will independently screen the titles and abstracts from 
the search results using the predefined eligibility criteria. A 
calibration exercise will be performed on the first 50 studies to 
refine the screening question prior to formally commencing 
the screening process. Two review authors will assess the 
eligibility of the full-text articles. Discrepancies between the 
reviewers will be resolved by discussion or with a third-party 
member if consensus cannot be established. Reasons for 
excluding studies will be recorded.
Data collection process and data items. Standardized forms 
designed in DistillerSR will be used to extract all study 
characteristics (see list below). Following a pilot to refine the 
forms and a calibration exercise to ensure high inter-rater 
agreement (i.e. above 80%), data will be extracted independ-
ently by two reviewers. Disagreements between reviewers will 
be resolved by discussion or with a third-party member if a 
consensus cannot be reached. The following data will be 
collected from eligible preclinical articles, and many of 
these elements will be incorporated for analyses listed in 
Objective #2. Data items i–v will be collected from all eligible 
preclinical articles. Data items vi–x will only be collected from 
articles selected as either cases or controls in Objective #2:
   i.    Funding: academic/governmental/charitable vs. biotech-
nology and/or pharmaceutical companies (defined as 
reported industry affiliation by an author, financial sup-
port, or provision of the therapy being studied)
  ii.    Study characteristics: study title, first and correspond-
ing authors’ name, publication year, journal of publica-
tion, country of corresponding author, and the number of 
authors and affiliated institutions
 iii.    Study population: animal species, sex, age, presence of 
comorbid illnesses
  iv.    Type of model: disease being studied, name of animal 
model(s) used, number of different models used
   v.    Interventions (promising therapy): name of interven-
tion, dose-response tested, anticipated application (e.g. 
preventative, therapeutic, or both)
  vi.    Preclinical outcomes: primary outcome (or, if none 
declared, main in vivo outcome highlighted by authors), 
death, adverse events
 vii.    Risk of bias (internal validity): the Cochrane Risk of Bias 
tool to evaluate preclinical in vivo studies19
viii.    External validity (range of experimental conditions 
tested): more than one animal model used (species or 
disease model/co-morbid model), inclusion of male and 
female animals, and multiple treatment doses
  ix.    Completeness of reporting: an operationalized version 
of the National Institutes of Health Preclinical Reporting 
guidelines will be used22.
   x.    Article metrics: The H-index of the corresponding 
author(s) and the number of times the paper has been 
cited
Identifying clinical translation of promising bench findings. 
After identifying the set of promising potential therapies, the 
stage of clinical translation that each therapy has achieved will be 
identified. In collaboration with an information specialist 
(L. Sikora), a piloted algorithmic search strategy that identifies 
the current state of clinical use will be used. Backward citation 
analysis (identifying and examining the studies cited in an 
article) and forward citation analysis (identifying studies that 
cite an original article or work after it had been published) 
will be used. The search strategy consists of searching known 
databases for citation analysis (i.e. Scopus, ISI Web of Science, 
Google Scholar). Other resources will also be searched including 
grey literature sources, clinical trial registries, clinical practice 
guidelines, and conference proceedings. The full draft 
algorithm is listed in Extended data. This approach will be used 
to determine the furthest stage of clinical testing and whether the 
agent has received regulatory approval.
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Outcomes. The primary outcome of interest will be the 
successful clinical translation of the identified promising 
therapies defined as 1) having obtained regulatory approval for 
the therapy, or 2) the conduct of at least one Phase II trial (or 
greater) for efficacy, with a statistically significant result 
favoring the treatment (and no later trials with negative or 
null results). As per the Federal Drug Agency (FDA) in the 
United States, the purpose of Phase II trials is “efficacy as 
well as side effects.�23 A positive finding will be defined as 
a statistically significant result demonstrating therapeutic 
superiority compared to placebo/no treatment, or established 
interventions; or stated non-inferiority compared to currently 
established interventions in an appropriate designed and 
conducted clinical study. This primary outcome has been selected 
as it indicates replication of the findings from the animal mod-
els of the preclinical study in the human subjects of the clinical 
trial.
The secondary outcome is the furthest clinical advances of all 
promising therapies from Phase I through to regulatory 
approval. For this outcome we will consider any clinical trial 
that has been performed and/or published. Whether favorable 
results were obtained for each identified trial (which we will 
call a “positive� trial) will also be reported. As above, a 
positive result will be defined by a statistically significant result 
demonstrating superiority compared to placebo/no treatment, or 
established interventions; or stated non-inferiority compared to 
currently established interventions. In determining regulatory 
approval status, while the dominant regulatory agencies are often 
regarded as the FDA (US), European Medical Agency (Europe), 
and Pharmaceuticals and Medical Devices Agency (Japan), 
approval by any regulatory agency will be accepted. This 
outcome will be presented as a proportion of studies that 
advanced to the clinical trial stage. Results will also be stratified 
by year of publication: 24–20 years ago (to provide a compari-
son to the landmark article by Contopoulos-Ioannidis et al.5), 
20–10 years ago, and <10 years ago.
Data synthesis and analysis plan. The total number of studies 
screened, assessed for eligibility, and included in the review 
(with reasons for exclusion) will be reported according to the 
PRISMA guidelines for reporting systematic reviews24. For 
each included study, the characteristics outlined above will be 
described, with frequencies and proportions reported. Addi-
tionally, we will calculate the proportion of successful Phase 
II trials that received regulatory approval. For the primary 
outcome, the time from the preclinical paper publication 
date, to first positive Phase II trial will be calculated and pre-
sented. Likewise, for the secondary outcomes, the time to 
furthest advance (Phase I, II, III, IV, or approval), as well 
time to first positive trial will be calculated using medians 
and interquartile ranges. Kaplan-Meier curves will also be 
constructed for all time to event analyses. All analyses will be 
performed using SAS (Version 9.4).
For all promising therapies, a descriptive analysis of all study 
characteristics and its research trajectory (i.e. furthest level of 
human experimentation) will be presented. This will present 
the cohort of successful and unsuccessful promising therapies 
published in highly influential journals, as well as the 
ability to evaluate secular trends in translation.
Risk of bias assessment. Risk of bias will be assessed in 
duplicate by two independent reviewers as high, low or unclear 
for six domains of bias identified by the Cochrane Risk of Bias 
tool19, with the addition of two domains suggested to influence 
the risk of bias in preclinical studies25. Disagreements will be 
resolved first by discussion and subsequently by consulting 
a third-party member, if needed. Graphic representations 
of risk of bias within and across studies will be conducted 
using RevMan 5.3 (Cochrane Collaboration, Oxford, United 
Kingdom).
Objective #2
A case-control study will be performed to evaluate the 
association between preclinical study characteristics and the 
incidence of translation. Translated therapies gaining regulatory 
approval or into a Phase II clinical trial (or later) will be 
defined as cases; unsuccessfully translated therapies will serve 
as controls. This study will help identify factors of internal 
and/or external validity, which are associated with “failed� 
versus “successful� translation. A case-control design was 
chosen as the most efficient methodological design due to 
i.) the rarity of preclinical to clinical translation and ii.) the 
ability to study multiple factors that may contribute to translational 
success.
Data source, identification and matching of cases and 
controls. Upon completion of the cross-sectional study outlined 
in Objective #1, a comprehensive roster of promising basic 
science findings published in top-tier journals between 1995 
and 2015 will be generated. From this dataset, cases and matched 
controls will be selected:
Cases: Promising discoveries that became successfully translated 
will be used as cases in our study. ‘Successfully translated’ 
will be defined in two ways as mentioned above. In keeping 
with the primary outcome in Objective #1, successful trans-
lation will be defined as having 1) obtained approval from a 
regulatory agency and/or 2) demonstrated positive findings in 
a Phase II clinical trial of efficacy - indicating replication of 
the findings from the preclinical study. As in Objective #1, a 
positive result will be defined by a statistically significant result 
demonstrating superiority compared to placebo/no treatment, 
or established interventions; or stated non-inferiority compared 
to currently established interventions.
Controls: Highly promising basic science findings which were 
not successfully translated will serve as controls. Unsuccessful 
translation will be defined as either a highly promising basic 
science finding without 1) having obtained regulatory approval, 
AND 2) any clinical trial (i.e. no trial identified by literature 
search and/or identified in clinical trial registries such as 
clinicaltrials.gov) or going to trial and failing for any reason 
(e.g. failing in safety in Phase I; or efficacy in Phase II). If 
possible, up to 4 matched controls per case will be selected. 
This 4:1 ratio represents the most statistically efficient ratio 
while minimizing bias introduced to the study26,27. Controls 
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will be frequency matched based on year of publication (+/- 5 
years for each case, disease of interest, and general area of 
biomedical research (i.e. cardiology, cancer, immunotherapy, 
etc.)). These stratifying factors are not predictor variables but 
have been chosen to ensure the comparability of cases and 
controls in the sample. Following matching, controls will be 
randomly selected using a computer-generated algorithm for 
those cases with >4 matched controls.
Variables. The primary analysis will investigate the association 
between a set of variables thought to influence translation, and 
successful translation. It is hypothesized that the following four 
sets of variables are of high importance:
i.     Internal validity: Similarly to clinical studies, preclinical 
studies that lack methodological rigor usually demonstrate 
the largest measures of efficacy28–30. However, this lack 
of methodological rigor may reduce the likelihood that 
these studies can be translated. In our study, risk of 
bias will be assessed by applying the Cochrane Risk of 
Bias tool19 – modified for suitability to preclinical 
studies. We will assess six domains identified by this tool 
(sequence generation, allocation concealment, blinding 
of personnel, blinding of outcome assessors, incomplete 
outcome data, and selective outcome reporting), as 
well as two additional risk of bias domains (conflict of 
interest and sample size calculation) for a total of 
eight risk of bias domains. Again, this checklist will be 
operationalized into a binary outcome; if the majority 
(i.e. >4) of items on the checklist are met the study will be 
considered to have high internal validity.
ii.     External validity: This will be assessed by the 
experiment(s) within the preclinical study being per-
formed across a range of conditions: the presence of 
dose response relationship, more than one animal model 
(species or method of disease induction) used, male 
and female animals (or the appropriate sex for sex 
specific diseases, e.g. prostate or ovarian cancer), and 
co-morbid animals31. This outcome will be dichot-
omized, (i.e. if two or more of these four criteria are 
met, the study will be considered to have high external 
validity).
iii.     Funding source: Evidence suggests that industry 
involvement may lead to faster translation5. This rela-
tionship will be examined by determining if the 
preclinical study involving the promising therapy was 
industry, government, or philanthropy funded (with 
attention also given to whether industry funding was 
from pharmaceutical or biotechnology companies).
iv.     Completeness of reporting: The National Institutes 
for Health preclinical reporting guidelines will be 
used to assess completeness of reporting. We have 
previously operationalized this list into 21 yes or no 
questions. This outcome will be dichotomized as high 
or low completeness of reporting when the majority of 
items (≥11) are reported upon or not. As a pre-planned 
sensitivity analysis, we will also evaluate the preclinical 
studies as high completeness of reporting when they 
report on over two thirds of the checklist items (≥14).
For the exposure items of validity (internal and external) 
and reporting the individual items in each checklist will not be 
weighted.
Exploratory analysis:
i. Individual components of internal validity: We will assess 
two selected risk of bias domains (sequence generation and 
blinding of outcome assessor) individually.
ii. Individual components of external validity: We will assess 
all components of external validity individually, rather than as 
an aggregate outcome.
iii. Number of authors and institutions: We will use the 
number of co-authors and the number of affiliated institutions 
on the preclinical paper as an approximation for the degree of 
collaboration within the preclinical study. With this, we plan to 
evaluate how the degree of collaboration within a preclinical study 
affects translation.
iv. H-index: We will use the corresponding author’s H-index as 
an approximation for investigator seniority. With this, we plan 
to evaluate how the corresponding author’s seniority affects 
preclinical to clinical translation.
v. Number of citations: We will use the number of citations 
associated with the preclinical paper as an approximation for 
the degree of dissemination. With this we plan to evaluate 
how the degree of the preclinical study’s dissemination affects 
translation.
Data analysis and sample size
Sample size. In a preliminary screen of Science and Nature, 
482 promising therapies (184 Science; 298 Nature) were 
identified. Application of a conservative estimate suggests that 
the addition of the third journal (Nature Medicine) will 
provide an additional 150 promising therapies, for a total of 
632. In the previous report citing a 5% translation rate17, 19 of 
101 (19%) promising therapies reached the clinical trial stage 
and demonstrated favorable results. Methodological differ-
ences between this study and the previous report may lead to a 
decrease in the percentage of promising therapies demonstrat-
ing favorable results at phase II. A conservative estimate of 
half the rate from the previous report (9.5%) suggests that 
roughly 60 of the promising therapies from our sample would 
demonstrate promising results at phase II or later. Generally, it 
is recommended that a regression model contain 10 events per 
variable32,33. Considering the four variables listed above, we will 
require 40 cases in order to be adequately powered to perform 
our proposed analysis.
If an adequate sample size of 40 cases is not reached, we 
will continue searching for promising preclinical therapies in 
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order to identify additional phase II or later translated thera-
pies. The CAMARADES group has used a machine learning 
algorithm34 to identify a cohort of over 100,000 reports of 
in vivo research available on PubMed Central. From this 
we will randomly select reports of in vivo preclinical research 
and assess these for clinical translation. The number of stud-
ies randomly selected will depend on the number of additional 
case required. We will sample iteratively until our predetermined 
minimal set of 40 cases is obtained.
Analytic plan. A comparison of baseline variables (aside 
from matching factors) in the cases and controls will be 
assessed using frequency distributions and univariate descrip-
tive statistics including measures of central tendency and 
dispersion. Multivariable conditional logistic regression will 
be performed to determine the adjusted association of our 
factors to the outcome variable. Odds ratios with accompany-
ing 95% confidence intervals will be calculated. A sensitivity 
analysis will be performed excluding cases that had a positive 
clinical trial but had not received regulatory approval. All 
analyses will be performed using SAS (version 9.4). Data will 
be presented as odds-ratios and 95% confidence intervals in 
forest plots.
Limitations
Our focus on leading journals (Science, Nature and Nature 
Medicine) may be perceived as a limitation. Given the usually 
positive findings and higher visibility of studies published 
therein, this may lead to an over-estimate in the bench-to-
bedside translation. Although this selection of journals may 
represent an over-estimate of translation, we also believe it 
represents the ‘best-in-class’ of preclinical research. Alterna-
tively, the reliance upon publicly available data may result in an 
under-estimate of the bench-to-bedside transition as it is 
possible that preclinical work from within industry that does 
not proceed to a clinical trial may not be published. Without 
examining this omitted data, we may not be presenting a fully 
accurate assessment of the state of preclinical to clinical trial 
translation. Furthermore, our sample is limited to three jour-
nals, which may reduce the scope of our work. As automation 
of meta-research projects gains traction (and tools are vali-
dated) broader searches will certainly be possible in the future. 
However, given that this process currently relies on personnel 
we are limited to the current strategy. Another limita-
tion is that components of internal validity have histori-
cally been poorly reported in bench research35, which 
may not be an accurate reflection of what investigators actually 
did. A third limitation is that the dichotomization of variables 
in the case-control could be regarded as an oversimplifica-
tion of complex concepts. However, our exploratory analyses 
will allow us to investigate a larger number of factors in 
more granular detail. Furthermore, our assessment on the 
external validity and how this may affect translation rests on the 
assumption that the rationale for initiating a clinical trial is based 
solely on one preclinical study, rather than several studies from 
different labs under a range of conditions. In reality, external 
validity would be best established through multiple preclinical 
experiments rather than one with a high level of external 
validity.
Another important aspect affecting the quality of preclinical 
evidence is construct validity. Studies have demonstrated that 
poor construct validity affects reproducibility and downstream 
clinical translation36,37. Though a checklist to assess construct 
validity has been developed31, after pilot testing this tool we 
found that it was infeasible for our study, as it required 
content expertise for every promising therapeutic to be used 
appropriately. Thus, another limitation of this study is that we 
are unable to evaluate the construct validity of the preclinical 
studies and assess how this aspect affects the translation into 
clinical trials.
Lastly, it should be acknowledged that the translational spec-
trum involves many complex steps and various phases. Though 
ultimate clinical translation is the approval and adoption 
of a therapy, we will focus on a specific stage in the transla-
tional spectrum1. We have chosen to measure the translation 
of the in vivo animal experiment stage within T0 research; to 
the first evaluation of the therapy’s efficacy in clinical trials, 
within T2 research. When we deem a successful translation from 
preclinical to clinical research, we do not evaluate all stages 
of preclinical nor clinical research. Furthermore, success-
ful translation to a Phase II clinical trial does not imply that the 
therapy has been successfully translated to practice or regulatory 
approval; and regulatory approval may not guarantee widespread 
adoption. With this limitation in mind, we will focus on preclini-
cal issues that may affect early translation, rather than poten-
tial issues with the clinical trials that subsequently evaluated the 
therapies in human subjects or barriers that affect both regula-
tory approval and adoption into practice We anticipate a future 
study that will critically analyze the translational clinical tri-
als identified in Objective #1 to address issues associated with 
those trials.
Dissemination
We will have a one-day, in-person meeting between the 
investigators and identified knowledge users (Stem Cell Network 
and BioCanRx, two Government of Canada funded Networks 
of Centres of Excellence focused on the development of novel 
therapeutics). Over the one-day meeting we will examine data 
and results generated by the project. In addition, each knowledge 
user will speak about their organization’s experiences and 
perspectives on bench-to-bedside translation. The meeting 
will end with a discussion to identify next steps to be taken by 
stakeholders to improve translation.
We anticipate the publication of two key papers submitted to 
appropriate peer-reviews journals. The first will describe key 
findings of the systematic review and present the results of 
our case-control study. The second will be a policy piece to 
describe how our findings may affect stakeholders across the 
spectrum of bench-to-bedside research. The results of this 
study will be presented at relevant national and international 
scientific meetings to promote knowledge transfer.
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Amendments
If amendments are required for this protocol, the date of each 
amendment will be provided with a description for rationale 
for the change in this section.
Study status
With our systematic search strategy, we have searched the 
journals Science, Nature, and Nature Medicine and are currently 
screening articles to identify promising therapies as per Objective 
#1 of this study.
Discussion
This study is an innovative project that will use knowledge 
synthesis methods to identify the incidence of successful trans-
lation, map contemporary trends in translation, and identify 
key modifiable factors associated with successful and unsuc-
cessful bench-to-bedside translation. Additionally, the proposed 
study will generate the largest dataset to date of promising 
preclinical therapies and then apply a case-control design to 
investigate the association of validities with successful or 
failed translation. This evidence is required to implement a 
“knowledge-to-action�38–40 cycle to improve bench-to-bedside 
translational research.
Current lags in translation are unknown. Some of our own 
efforts (and others) at translation suggest that these lags 
between preclinical findings and first-in-human trials may be 
shortening25,41–44. This reduction may reflect increased funding 
towards translational activities, improved research rigor, as well 
as regulatory changes that have accelerated translation efforts 
(e.g. FDA’s four unique approaches of Fast Track, Breakthrough 
Therapy, Accelerated Approval, and Priority Review). If this 
hypothesis is supported by the data, all stakeholders need 
information about the factors that support improvements in 
development timelines.
The effect of evolving preclinical reporting guidelines on 
translation is unknown. In the last decade, funders, journals, 
and other stakeholders have endorsed reporting guidelines35,45 
that improve transparency and potentially improve the ability to 
forecast which interventions may translate successfully. 
These guidelines have been developed in response to multiple 
publications, which demonstrated that the majority of basic 
science findings are irreproducible46–48. Previous studies of 
bench-to-bedside translation were conducted prior to these 
guidelines being widely endorsed; thus, a current study is needed 
to determine if increased awareness and emphasis regarding 
preclinical reporting and design has improved translation.
Taken together, there is a strong need and justification for the 
proposed study. This study will provide a contemporary under-
standing of bench-to-bedside translation, which is required to 
tailor experimental designs to improve translational efficiency, 
including the education and uptake of available study design and 
analysis methods.
Data availability
Underlying data
No data is associated with this article.
Extended data
Open Science Framework: Identifying and understand-
ing factors that affect the translation of therapies from the 
laboratory to patients, https://doi.org/10.17605/OSF.IO/ 
WGZ3T21.
This project contains the following extended data:
-     Representative search strategy in PubMed
-     Data selection items
-      Algorithm to identify clinical translation of promising 
bench findings
Data are available under the terms of the Creative Commons 
Zero “No rights reserved� data waiver (CC0 1.0 Public domain 
dedication).
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John Holcomb  
Division of Acute Care Surgery, Department of Surgery, University of Alabama at Birmingham, 
Birmingham, AL, USA 
The authors have embarked on an important project. They will evaluate the issues related to 
translation of preclinical data into clinical practice. 
I have several comments.
The authors should clearly state the narrow focus of their work, largely in the drug 
development arena. They seem to exclude other research areas such as devices and blood 
products. Please inform the reader what focus areas are included and excluded. 
 
1. 
The authors have included only several journals to review. Given the ability to use electronic 
databases, I would suggest they broaden their search. 
 
2. 
Lastly, the definition of clinical translation is not completion of phase 2 studies, but rather 
regulatory approval and adoption into clinical practice. Defining adoption itself is difficult, 
and should be discussed.  
3. 
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 08 Oct 2020
Manoj Lalu, Ottawa General Hospital Research Institute, Ottawa, Canada 
We thank you for your careful assessment of our protocol and their supportive 
comments. We have addressed your queries below and within the revised manuscript. 
 
The authors have embarked on an important project. They will evaluate the issues related to 
translation of preclinical data into clinical practice. I have several comments. 
 
The authors should clearly state the narrow focus of their work, largely in the drug 
development arena. They seem to exclude other research areas such as devices 
and blood products. Please inform the reader what focus areas are included and 
excluded.
1. 
  
We apologize for the lack of clarity on our inclusion criteria. Our search and strategy 
for selecting therapies is designed to consider all interventions that have therapeutic 
benefit.  We added blood products and devices in the examples of ‘promising 
therapies’ in the inclusion criteria.   
 
 A ‘promising therapy’, defined by the following: 
a. Any therapy introduced to the animal model (e.g. pharmacologic and non-pharmacologic 
therapies, vaccines, antibodies, blood products, implants/devices, etc.), which was still at 
the developmental stage and did not have a prior application in humans for the specific 
indication. 
 
The authors have included only several journals to review. Given the ability to use 
electronic databases, I would suggest they broaden their search.
1. 
  
Our group of investigators considered this very issue at length. Ultimately, there 
simply is no perfect sampling strategy to address the objectives of the study. We 
selected the three journals as they are highly influential and considered ‘best-in-class’ 
by many. The number of articles resulting from the search of the three included 
journals is 20,341. With our available resources, it has taken close to one year to 
screen all abstracts and full texts in duplicate. Adding more journals would not be 
feasible with our finite resources. We added the following to the limitation section of 
the discussion: 
  
Furthermore, our sample is limited to three journals, which may reduce the scope of our 
work. As automation of meta-research projects gains traction (and tools are validated) 
broader searches will certainly be possible in the future.  However, given that this process 
currently relies on personnel we are limited to the current strategy.   
 
Lastly, the definition of clinical translation is not completion of phase 2 studies, but 1. 
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rather regulatory approval and adoption into clinical practice. Defining adoption itself 
is difficult, and should be discussed.  
  
We agree that full clinical translation is not the completion of a Phase II trial and we 
also do agree that ultimate clinical translation is the clinical adoption of a therapy. In 
the current study we are focussed on the translation of preclinical research to first 
studies demonstrating efficacy in clinical trials. Full clinical translation to approved 
therapies will also be tracked and we will certainly be reporting on this metric as well. 
  
We have added/modified a sentence in the manuscript to further explain our 
intention:  
  
Therefore, the aim of this project is to use established knowledge synthesis methods to 
identify the prevalence of translation from preclinical research (bench) to the first clinical 
evaluations of efficacy (bedside), map contemporary trends in translation, and identify key 
modifiable factors associated with successful and unsuccessful bench-to-bedside 
translation. 
  
We added the following sentence in the analysis plan of Objective 1: 
  
Additionally, we will calculate the proportion of successful Phase II trials that received 
regulatory approval.  
  
We also added and modified the following in our limitations section:  
  
Lastly, it should be acknowledged that the translational spectrum involves many complex 
steps and various phases. Though ultimate clinical translation is the approval and 
adoption of a therapy, we will focus on a specific stage in the translational spectrum 4. We 
have chosen to measure the translation of the in vivo animal experiment stage within T0 
research to the first evaluation of the therapy’s efficacy in clinical trials, within T2 
research.  
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